Inclusion Criteria:

          -  The patient has provided written informed consent prior to any study-related
             procedure.

          -  The patient is at least 18 years of age

          -  Histologically proven locally advanced unresectable, recurrent and/or metastatic
             squamous cell carcinoma of the oropharynx, hypopharynx, larynx or oral cavity not
             amenable for salvage surgery

          -  p16 status has to be determined for oropharyngeal carcinomas

          -  Documented progressive disease based on investigator assessment according to RECIST
             1.1, following receipt of a pembrolizumab based regimen given as first line therapy
             for R/M SCCHN

          -  Measurable disease according to RECIST 1.1.

          -  The patient has a life expectancy of at least 3 months.

          -  Has a performance status of ≤ 2 on the ECOG Performance Scale

          -  Female patient of childbearing potential should have a negative urine or serum
             pregnancy prior to study . If the urine test is positive or cannot be confirmed as
             negative, a serum pregnancy test will be required.

          -  Female patients of childbearing potential should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study until 120 days after the last dose of study medication. Patients of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for > 1 year.

          -  Male patients should agree to use an adequate method of contraception starting with
             the first dose of study therapy until 120 days after the last dose of study therapy.

          -  Demonstrate adequate organ function as defined in table 1, all screening labs should
             be performed within 14 days of treatment initiation.

        Exclusion Criteria:

          -  Prior taxane therapy is not allowed except as part of induction therapy for locally
             advanced disease (completed at least 6 months before study entry)

          -  Prior cetuximab therapy is not allowed except as part of either induction therapy or
             in combination with radiotherapy treatment for locally advanced disease (completed at
             least 6 months before study entry)

          -  Patients with nasopharyngeal carcinomas or salivary glands cancers

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy within 4 weeks of the first
             dose of treatment.

          -  Has a diagnosis of immunodeficiency including a known history of Human
             Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has known active Hepatitis A/B or Hepatitis C

          -  Has had prior pembrolizumab within 2 weeks prior to study day 1 or who has not
             recovered (i.e., recovery to ≤ Grade 1 or baseline grade prior to pembrolizumab) from
             (immune- related) adverse events other than endocrine side effects.

          -  Has had prior chemotherapy or radiation therapy within 2 weeks prior to study day 1 or
             who has not recovered (i.e., recovery to ≤ Grade 1 or baseline grade prior to
             pembrolizumab) from adverse events due to a previously administered agent.

          -  Has had chemotherapy, targeted therapy or investigational drugs after checkpoint
             inhibitor failure for second line therapy .

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

          -  Has an active infection requiring systemic therapy.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the patient's
             participation for the full duration of the trial, or is not in the best interest of
             the patient to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             until 120 days after the last dose of trial treatment.